This study aims to investigate the epidemiology of SARS-CoV-2 infection among: i) HCW who triage patients with suspected SARS-CoV-2 infection and provide care to COVID-19 patients; and ii) laboratory personnel who test clinical samples for SARS-CoV-2 infection. After the second wave of the pandemic enrolment will be widen to any person working at the study hospitals.
Study Type
OBSERVATIONAL
Enrollment
512
Chris Hani Baragwanath Academic Hospital
Johannesburg, GP, South Africa
To determine the prevalence of symptomatic and asymptomatic SARS-CoV-2 infections among HCW.
To determine the prevalence of symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infections among HCW using a systematic sampling strategy, coupled with investigation when clinically indicated.
Time frame: 2020
To define the duration of viral "shedding".
To define the duration of "shedding" (using molecular based PCR methods) of SARS-CoV-2 in HCW who are identified to be infected with the virus.
Time frame: 2020
To do sero-epidemiology assessment.
To undertake serial sero-epidemiology studies on prevalence of SARS-CoV-2 antibodies among HCW.
Time frame: 2022
To analyse immune responses to SARS-CoV-2 infection.
To analyse immune responses (humoral and cell mediated) to SARS-CoV-2 infection.
Time frame: 2022
To investigate the possibility of viral re-infection in this population during the study period.
To investigate the possibility of viral re-infection during the different pandemic waves in this population during the study period.
Time frame: 2022
To establish if common cold coronaviruses (CCCV) immunity confers protection against SARS-CoV-2 infection or disease severity
To establish if common cold coronaviruses (CCCV) immunity confers protection against SARS-CoV-2 infection or disease severity by measuring antibodies to CCCV.
Time frame: 2022
To evaluate COVID-19 vaccine effectiveness (VE) amongst HCWs, against any PCR-confirmed SARS-CoV-2 infection.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
To evaluate COVID-19 vaccine effectiveness (VE) amongst HCWs, against any PCR-confirmed SARS-CoV-2 infection.
Time frame: 2022
To measure humoral and cell mediated immune responses to COVID-19 vaccines stratified by previous SARS-CoV-2 infection.
To measure humoral and cell mediated immune responses to COVID-19 vaccines stratified by previous SARS-CoV-2 infection.
Time frame: 2022